Literature DB >> 29376650

Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates.

Rubina Giare Parmar1, Christopher R Brown1, Shigeo Matsuda1, Jennifer L S Willoughby1, Christopher S Theile1, Klaus Charissé1, Donald J Foster1, Ivan Zlatev1, Vasant Jadhav1, Martin A Maier1, Martin Egli2, Muthiah Manoharan1, Kallanthottathil G Rajeev1.   

Abstract

(E)-Vinylphosphonate ((E)-VP), a metabolically stable phosphate mimic at the 5'-end of the antisense strand, enhances the in vivo potency of siRNA. Here we describe a straightforward synthetic approach to incorporate a nucleotide carrying a vinylphosphonate (VP) moiety at the 5'-end of oligonucleotides under standard solid-phase synthesis and deprotection conditions by utilizing pivaloyloxymethyl (POM) protected VP-nucleoside phosphoramidites. The POM protection enhances scope and scalability of 5'-VP-modified oligonucleotides and, in a broader sense, the synthesis of oligonucleotides modified with phosphonate moieties. Trivalent N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) comprising (E)-geometrical isomer of VP showed improved RISC loading with robust RNAi-mediated gene silencing in mice compared to the corresponding (Z)-isomer despite similar tissue accumulation. We also obtained structural insights into why bulkier 2'-ribosugar substitutions such as 2'-O-[2-(methylamino)-2-oxoethyl] are well tolerated only when combined with 5'-(E)-VP.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29376650     DOI: 10.1021/acs.jmedchem.7b01147

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Strategies, design, and chemistry in siRNA delivery systems.

Authors:  Yizhou Dong; Daniel J Siegwart; Daniel G Anderson
Journal:  Adv Drug Deliv Rev       Date:  2019-05-15       Impact factor: 15.470

Review 2.  Improving siRNA Delivery In Vivo Through Lipid Conjugation.

Authors:  Maire F Osborn; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2018-05-10       Impact factor: 5.486

3.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

4.  Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing.

Authors:  Hartmut Jahns; Rohan Degaonkar; Peter Podbevsek; Swati Gupta; Anna Bisbe; Krishna Aluri; John Szeto; Pawan Kumar; Sarah LeBlanc; Tim Racie; Christopher R Brown; Adam Castoreno; Dale C Guenther; Vasant Jadhav; Martin A Maier; Janez Plavec; Martin Egli; Muthiah Manoharan; Ivan Zlatev
Journal:  Nucleic Acids Res       Date:  2021-10-11       Impact factor: 16.971

Review 5.  Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications.

Authors:  Sumit Gangopadhyay; Kiran R Gore
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.652

6.  Synthesis and evaluation of (S)-5'-C-aminopropyl and (S)-5'-C-aminopropyl-2'-arabinofluoro modified DNA oligomers for novel RNase H-dependent antisense oligonucleotides.

Authors:  Yujun Zhou; Ryohei Kajino; Seiichiro Ishii; Kenji Yamagishi; Yoshihito Ueno
Journal:  RSC Adv       Date:  2020-11-17       Impact factor: 4.036

7.  Role of a "Magic" Methyl: 2'-Deoxy-2'-α-F-2'-β-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5'-Phosphate Mimics and Mitigation of Off-Target Effects.

Authors:  Dale C Guenther; Shohei Mori; Shigeo Matsuda; Jason A Gilbert; Jennifer L S Willoughby; Sarah Hyde; Anna Bisbe; Yongfeng Jiang; Saket Agarwal; Mimouna Madaoui; Maja M Janas; Klaus Charisse; Martin A Maier; Martin Egli; Muthiah Manoharan
Journal:  J Am Chem Soc       Date:  2022-08-03       Impact factor: 16.383

8.  Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.

Authors:  Christopher R Brown; Swati Gupta; June Qin; Timothy Racie; Guo He; Scott Lentini; Ryan Malone; Mikyung Yu; Shigeo Matsuda; Svetlana Shulga-Morskaya; Anil V Nair; Christopher S Theile; Karyn Schmidt; Azar Shahraz; Varun Goel; Rubina G Parmar; Ivan Zlatev; Mark K Schlegel; Jayaprakash K Nair; Muthusamy Jayaraman; Muthiah Manoharan; Dennis Brown; Martin A Maier; Vasant Jadhav
Journal:  Nucleic Acids Res       Date:  2020-12-02       Impact factor: 16.971

9.  Structural basis for the synergy of 4'- and 2'-modifications on siRNA nuclease resistance, thermal stability and RNAi activity.

Authors:  Joel M Harp; Dale C Guenther; Anna Bisbe; Lydia Perkins; Shigeo Matsuda; Gopal R Bommineni; Ivan Zlatev; Donald J Foster; Nate Taneja; Klaus Charisse; Martin A Maier; Kallanthottathil G Rajeev; Muthiah Manoharan; Martin Egli
Journal:  Nucleic Acids Res       Date:  2018-09-19       Impact factor: 16.971

10.  Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease.

Authors:  Pawan Kumar; Rohan Degaonkar; Dale C Guenther; Mikhail Abramov; Guy Schepers; Marie Capobianco; Yongfeng Jiang; Joel Harp; Charalambos Kaittanis; Maja M Janas; Adam Castoreno; Ivan Zlatev; Mark K Schlegel; Piet Herdewijn; Martin Egli; Muthiah Manoharan
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.